Filing Details

Accession Number:
0001104659-19-034351
Form Type:
4
Zero Holdings:
No
Publication Time:
2019-06-06 18:02:37
Reporting Period:
2019-06-04
Accepted Time:
2019-06-06 18:02:37
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1740547 Urovant Sciences Ltd. UROV () D0
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1635088 Ltd. Sciences Roivant Suite 1, 3Rd Floor
11-12 St. James'S Square
London X0 SW1Y 4LB
No No Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Shares, Par Value $0.000037453 Per Share Acquisiton 2019-06-04 7,500 $7.59 22,784,838 No 4 P Direct
Common Shares, Par Value $0.000037453 Per Share Acquisiton 2019-06-05 6,540 $8.02 22,791,378 No 4 P Direct
Common Shares, Par Value $0.000037453 Per Share Acquisiton 2019-06-06 7,082 $8.00 22,798,460 No 4 P Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 P Direct
No 4 P Direct
No 4 P Direct
Footnotes
  1. The transaction was a series of open market purchases made by Roivant Sciences Ltd. ("Roivant") under a trading plan established by Roivant pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and in accordance with the safe harbor of Rule 10b-18 under the Exchange Act.
  2. The price reported in Column 4 is a weighted average price. These Common Shares were purchased in multiple transactions at prices ranging from $7.42 to $7.71, inclusive. The reporting person undertakes to provide to Urovant Sciences Ltd. ("Urovant"), any security holder of Urovant, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of Common Shares purchased at each separate price within the range set forth in this footnote (2) to this Form 4.
  3. The price reported in Column 4 is a weighted average price. These Common Shares were purchased in multiple transactions at prices ranging from $7.68 to $8.33, inclusive. The reporting person undertakes to provide to Urovant, any security holder of Urovant, or the staff of the SEC, upon request, full information regarding the number of Common Shares purchased at each separate price within the range set forth in this footnote (3) to this Form 4.
  4. The price reported in Column 4 is a weighted average price. These Common Shares were purchased in multiple transactions at prices ranging from $7.73 to $8.57, inclusive. The reporting person undertakes to provide to Urovant, any security holder of Urovant, or the staff of the SEC, upon request, full information regarding the number of Common Shares purchased at each separate price within the range set forth in this footnote (4) to this Form 4.